Prosecution Insights
Last updated: April 19, 2026
Application No. 18/064,958

Pt-thixantphos-iodine complex and Pt-thixantphos-bromine complex

Final Rejection §103
Filed
Dec 13, 2022
Examiner
QIAN, YUN
Art Unit
1738
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Evonik Operations GmbH
OA Round
2 (Final)
54%
Grant Probability
Moderate
3-4
OA Rounds
3y 3m
To Grant
75%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allow Rate
588 granted / 1081 resolved
-10.6% vs TC avg
Strong +20% interview lift
Without
With
+20.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
60 currently pending
Career history
1141
Total Applications
across all art units

Statute-Specific Performance

§101
0.1%
-39.9% vs TC avg
§103
44.3%
+4.3% vs TC avg
§102
16.8%
-23.2% vs TC avg
§112
26.8%
-13.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1081 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Status of Claims Claims 1-11 currently under examination. Claim 12 is withdrawn from consideration. Claims 1-11 are amended. Previous Grounds of Rejection In the light of the amendments, the objections are withdrawn. Regarding claims 1-7, the rejection under 35 U.S.C. 103 as being unpatentable over Kranenburg et al. (Eur. J. Inorg. Cem., 1998, 155-157) stands. Previous Grounds of Rejections Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-7 are rejected under 35 U.S.C. 103 as being unpatentable over Kranenburg et al. (Eur. J. Inorg. Cem., 1998, 155-157). Regarding claim 1, Kranenburg et al. teach Pd complex or alternative Pt complex comprising thixantphos (3) which reacts with bromobenzene. As such, the bromide is bonded to Pd or alternative Pt as a ligand as shown in Figure 1 and Scheme 1 below (pages 155-156): PNG media_image1.png 98 142 media_image1.png Greyscale PNG media_image2.png 128 70 media_image2.png Greyscale As we see above, the thixantphos ligand corresponds to the instant claimed the ligand formula (I), wherein R1=R4=Me, R2=R3=H, R5-8=Ph. Regarding claims 2-5, as discussed above, the Pt complex taught by Kranenburg et al. comprise R5-8 as being phenyl groups, R1=R4=Me, R2=R3=H atoms. Regarding claim 6, as discussed above, the Pt complex taught by Kranenburg et al. corresponds to the compound as the instant claim. Regarding claim 7, as discussed above, the Pd-complex or alternative the Pt complex taught by Kranenburg et al. comprise a bromide ligand as shown in the Scheme 1. Allowable Subject Matter Claims 8-11 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Response to Arguments With regards to the previous Grounds of Rejection Applicant's arguments filed on 10/31/2025 have been considered but are not persuasive. The examiner would like to take this opportunity to address the Applicant's arguments. Applicant argued the breadth of the rejected claims may be the issue, specifically the bromine ligand present. Not directly mentioned in the Office is the scope of the ligand having formula I or formula 1. The structure and the presence of Pt would presumably be expected to be involved in the catalytic activity relied on (Remarks, page 4). The Office respectfully disagrees. As set forth in the previous non-final office action dated on 09/23/2025, Kranenburg et al. teach Pd complex or alternative Pt complex comprising thixantphos (3) which reacts with bromobenzene. As such, the bromide is bonded to Pd or alternative Pt as a ligand as shown in Figure 1 and Scheme 1 below (pages 155-156): PNG media_image1.png 98 142 media_image1.png Greyscale PNG media_image2.png 128 70 media_image2.png Greyscale As we see above, the thixantphos ligand corresponds to the instant claimed the ligand formula (I), wherein R1=R4=Me, R2=R3=H, R5-8=Ph. The thixantphos-Pt-Br(Ph) complex as shown in the above contains thixantphos ligand and bromine ligand as the instant claim. As such, the rejection of claim 1 as set forth in the office action mailed on 10/31/2025 is proper and stands. The rejection for the remaining claims, 2 through 7, were either directly or indirectly dependent thereon stands. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to YUN QIAN whose telephone number is (571)270-5834. The examiner can normally be reached Monday-Thursday 10:00am-4:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sally A Merkling can be reached at 571-272-6297. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. YUN . QIAN Examiner Art Unit 1732 /YUN QIAN/ Primary Examiner, Art Unit 1738
Read full office action

Prosecution Timeline

Dec 13, 2022
Application Filed
Sep 19, 2025
Non-Final Rejection — §103
Oct 31, 2025
Response Filed
Nov 15, 2025
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600906
RED-LUMINESCENT PHOSPHOR WITH LONG AFTERGLOW AND FABRICATION METHOD THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12595171
Co-production of Hydrogen and Sulfuric Acid by Partial Oxidation of Sulfur
2y 5m to grant Granted Apr 07, 2026
Patent 12592423
PROCESS AND ITS PRODUCTS FOR SPENT LITHIUM-ION BATTERIES TREATMENT
2y 5m to grant Granted Mar 31, 2026
Patent 12589383
Spherical Titanium Silicalite Molecular Sieve Catalyst and Preparation Method Therefor
2y 5m to grant Granted Mar 31, 2026
Patent 12577126
METHOD FOR PRODUCING NICKEL PARTICLES, METHOD FOR PRODUCING NICKEL SULFATE, AND METHOD FOR PRODUCING POSITIVE ELECTRODE ACTIVE MATERIAL FOR SECONDARY BATTERIES
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
54%
Grant Probability
75%
With Interview (+20.3%)
3y 3m
Median Time to Grant
Moderate
PTA Risk
Based on 1081 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month